Valuation: ProPhase Labs, Inc.

Market Cap 1.32M 1.15M 1.07M 995K 1.87M 125M 1.92M 12.82M 4.95M 61.49M 4.95M 4.84M 213M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.85M 8.62M 7.96M 7.43M 13.99M 931M 14.31M 95.78M 36.97M 459M 36.98M 36.17M 1.59B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-1.98%
1 week-16.18%
Current month-7.71%
1 month-20.17%
3 months+17.90%
6 months-79.66%
Current year-79.40%
1 week 0.09
Extreme 0.091
0.11
1 month 0.07
Extreme 0.0723
0.15
Current year 0.07
Extreme 0.068
0.47
1 year 0.07
Extreme 0.068
6.66
3 years 0.07
Extreme 0.068
75.9
5 years 0.07
Extreme 0.068
152.5
10 years 0.07
Extreme 0.068
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25Free

Chief Executive Officer

500,000 1.2036%
17/02/25Free

Chief Operating Officer

500,000 1.6737%
14/02/25Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-1.98%-16.18%-97.64%-99.87% 1.32M
-1.89%+14.61%+59.26%+452.92% 39B
-0.37%+7.49%+5.89%+15.18% 22.93B
-0.76%+4.94%-22.32%-41.50% 7.13B
-0.56%+5.41%+4.09%+81.61% 4.66B
-0.05%-1.40%+17.74%+45.72% 2.91B
-0.64%+19.74%-24.66%+1,066.86% 2.05B
-0.77%+24.24%+94.94%-11.33% 1.86B
+3.34%-0.56%+30.83%-21.79% 1.75B
+0.66%+1.66%+17.67%-4.55% 1.63B
Average -0.25%+12.74%+8.58%+148.33% 8.39B
Weighted average by Cap. -0.93%+14.01%+30.58%+242.50%

Financials

2024 2025
Net sales 6.77M 5.93M 5.47M 5.11M 9.62M 640M 9.84M 65.85M 25.42M 316M 25.42M 24.87M 1.1B 4.34M 3.8M 3.51M 3.28M 6.17M 411M 6.31M 42.27M 16.32M 203M 16.32M 15.96M 704M
Net income -53.36M -46.73M -43.14M -40.28M -75.83M -5.05B -77.55M -519M -200M -2.49B -200M -196M -8.64B -14.74M -12.91M -11.92M -11.13M -20.95M -1.39B -21.43M -143M -55.36M -688M -55.37M -54.15M -2.39B
Net Debt 23.9M 20.92M 19.32M 18.04M 33.95M 2.26B 34.73M 232M 89.73M 1.11B 89.74M 87.77M 3.87B 8.53M 7.47M 6.89M 6.44M 12.12M 806M 12.39M 82.95M 32.02M 398M 32.03M 31.32M 1.38B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
30/06/26 $0.0922 -1.98% 2,055
29/06/26 $0.0941 -5.94% 46,245
26/06/26 $0.1000 +9.77% 23,213
25/06/26 $0.0911 -4.61% 5,796
24/06/26 $0.0955 -13.18% 8,184

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock